Related Experiment Videos
Breast cancer--which patients?
1Scottish Cancer Trials Office, Edinburgh, UK.
Hormone Research
|January 1, 1989
Summary
Tamoxifen therapy is a key adjuvant treatment for postmenopausal breast cancer patients. Promising results are seen in node-positive disease, potentially influenced by receptor status.
Area of Science:
- Oncology
- Endocrinology
Background:
- Adjuvant therapy decisions for breast cancer are critical.
- Tamoxifen is a widely used endocrine therapy for postmenopausal women.
Purpose of the Study:
- To review current practices in adjuvant endocrine therapy for breast cancer.
- To identify patient subgroups who benefit most from tamoxifen.
Main Methods:
- Review of posters from the International Symposium on Endocrine Therapy.
- Analysis of treatment outcomes based on menopausal status and receptor status.
Main Results:
- Tamoxifen is the predominant adjuvant treatment for postmenopausal breast cancer.
- Node-positive patients show the most promising results with tamoxifen.
- Treatment efficacy may be linked to estrogen and progesterone receptor status.
Conclusions:
- Tamoxifen remains a cornerstone of adjuvant endocrine therapy for postmenopausal breast cancer.
- Further research may refine patient selection based on receptor status and cut-off levels.